Search results
Results from the WOW.Com Content Network
1,3-Dimethylbutylamine (1,3-DMBA, dimethylbutylamine, DMBA, 4-amino-2-methylpentane, or AMP), is a stimulant drug structurally related to methylhexanamine where a butyl group replaces the pentyl group. The compound is an aliphatic amine.
N-Methyl-1,3-benzodioxolylpentanamine (MBDP; Methyl-K, UWA-091), also known as 3,4-methylenedioxy-α-propyl-N-methylphenethylamine, is a psychoactive drug of the phenethylamine chemical class. It is the N-methyl analogue of 1,3-benzodioxolylpentanamine (BDP; K). Methyl-K was first synthesized by Alexander Shulgin ("Sasha" Shulgin).
4-Methylpentedrone (also known as 4-MPD and 4-Methyl-α-methylamino-valerophenone), is a stimulant drug of the cathinone class that has been sold online as a designer drug. It is a higher homolog of 4-methylmethcathinone (mephedrone) and 4-methylbuphedrone (4-MeMABP), and the p -methyl derivative of pentedrone .
This is a list of aminorex analogues. Aminorex itself is a stimulant drug with a 5-phenyl-2-amino-oxazoline structure. It was developed in the 1960s as an anorectic, [1] [2] [3] but withdrawn from sale after it was discovered that extended use produced pulmonary hypertension, often followed by heart failure, which resulted in a number of deaths. [4]
“You got all these people with this disease who need treatment,” he said. “There’s a medication that could really help us tackle this problem, help us dramatically reduce overdose death, and people are having a hard time accessing it.” The anti-medication approach adopted by the U.S. sets it apart from the rest of the developed world.
Methylhexanamine (also known as methylhexamine, 1,3-dimethylamylamine, 1,3-DMAA, dimethylamylamine, and DMAA; trade names Forthane and Geranamine) is an indirect sympathomimetic drug invented and developed by Eli Lilly and Company and marketed as an inhaled nasal decongestant from 1948 until it was voluntarily withdrawn from the market in the 1980s.
The drug is approximately 73% protein-bound across a plasma range of 7 to 226 ng/mL (28–892 nM). [1] The metabolism of nefopam is hepatic , by N - demethylation and via other routes . [ 1 ] Its terminal half-life is 3 to 8 hours, while that of its active metabolite , desmethylnefopam, is 10 to 15 hours. [ 1 ]
Thatch explains what qualifies as expenses for HRAs, QSEHRAs, and ICHRAs when it comes to medical costs, premiums, and more in this comprehensive guide.